Exact Sciences Corporation

NasdaqCM:EXAS Stock Report

Market Cap: US$12.4b

Exact Sciences Future Growth

Future criteria checks 4/6

Exact Sciences is forecast to grow earnings and revenue by 70.9% and 11.1% per annum respectively. EPS is expected to grow by 73.5% per annum. Return on equity is forecast to be 5.8% in 3 years.

Key information

70.9%

Earnings growth rate

73.5%

EPS growth rate

Biotechs earnings growth28.7%
Revenue growth rate11.1%
Future return on equity5.8%
Analyst coverage

Good

Last updated01 Oct 2024

Recent future growth updates

Recent updates

We Think Exact Sciences (NASDAQ:EXAS) Has A Fair Chunk Of Debt

Sep 25
We Think Exact Sciences (NASDAQ:EXAS) Has A Fair Chunk Of Debt

Exact Sciences: Cost Optimization And Product Strength

Aug 18

Exact Sciences Corporation's (NASDAQ:EXAS) Share Price Boosted 27% But Its Business Prospects Need A Lift Too

Aug 14
Exact Sciences Corporation's (NASDAQ:EXAS) Share Price Boosted 27% But Its Business Prospects Need A Lift Too

Exact Sciences: Still No Reason To Own

Jun 11

Revenues Working Against Exact Sciences Corporation's (NASDAQ:EXAS) Share Price Following 27% Dive

Jun 02
Revenues Working Against Exact Sciences Corporation's (NASDAQ:EXAS) Share Price Following 27% Dive

An Intrinsic Calculation For Exact Sciences Corporation (NASDAQ:EXAS) Suggests It's 46% Undervalued

Feb 23
An Intrinsic Calculation For Exact Sciences Corporation (NASDAQ:EXAS) Suggests It's 46% Undervalued

Investors Don't See Light At End Of Exact Sciences Corporation's (NASDAQ:EXAS) Tunnel

Jan 08
Investors Don't See Light At End Of Exact Sciences Corporation's (NASDAQ:EXAS) Tunnel

Exact Sciences Corporation (NASDAQ:EXAS) Shares Could Be 42% Below Their Intrinsic Value Estimate

Nov 15
Exact Sciences Corporation (NASDAQ:EXAS) Shares Could Be 42% Below Their Intrinsic Value Estimate

Exact Sciences (NASDAQ:EXAS) Is Carrying A Fair Bit Of Debt

Oct 04
Exact Sciences (NASDAQ:EXAS) Is Carrying A Fair Bit Of Debt

An Intrinsic Calculation For Exact Sciences Corporation (NASDAQ:EXAS) Suggests It's 44% Undervalued

Aug 14
An Intrinsic Calculation For Exact Sciences Corporation (NASDAQ:EXAS) Suggests It's 44% Undervalued

Here's Why Exact Sciences (NASDAQ:EXAS) Can Afford Some Debt

Jun 15
Here's Why Exact Sciences (NASDAQ:EXAS) Can Afford Some Debt

Calculating The Fair Value Of Exact Sciences Corporation (NASDAQ:EXAS)

Apr 26
Calculating The Fair Value Of Exact Sciences Corporation (NASDAQ:EXAS)

We Think Exact Sciences (NASDAQ:EXAS) Has A Fair Chunk Of Debt

Feb 23
We Think Exact Sciences (NASDAQ:EXAS) Has A Fair Chunk Of Debt

An Intrinsic Calculation For Exact Sciences Corporation (NASDAQ:EXAS) Suggests It's 45% Undervalued

Jan 10
An Intrinsic Calculation For Exact Sciences Corporation (NASDAQ:EXAS) Suggests It's 45% Undervalued

Earnings and Revenue Growth Forecasts

NasdaqCM:EXAS - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20263,62514670269317
12/31/20253,224-1341444523
12/31/20242,832-1679122523
6/30/20242,612-175-15119N/A
3/31/20242,535-240-20112N/A
12/31/20232,500-20432156N/A
9/30/20232,406-282-24139N/A
6/30/20232,301-432-10873N/A
3/31/20232,200-517-298-88N/A
12/31/20222,084-624-438-224N/A
9/30/20222,005-716-443-300N/A
6/30/20221,938-735-437-300N/A
3/31/20221,852-745-330-199N/A
12/31/20211,767-596-238-102N/A
9/30/20211,760-793-11734N/A
6/30/20211,712-82930156N/A
3/31/20211,546-72019109N/A
12/31/20201,491-82471136N/A
9/30/20201,321-327-890N/A
6/30/20201,131-165-238-111N/A
3/31/20201,062-136-262-87N/A
12/31/2019876-213-284-112N/A
9/30/2019724-216-271-88N/A
6/30/2019623-221-248-62N/A
3/31/2019526-219-250-105N/A
12/31/2018454-175-219-69N/A
9/30/2018399-143-203-69N/A
6/30/2018353-124-167-70N/A
3/31/2018308-119N/A-77N/A
12/31/2017266-114N/A-72N/A
9/30/2017214-130N/A-98N/A
6/30/2017169-141N/A-118N/A
3/31/2017133-155N/A-121N/A
12/31/201699-167N/A-130N/A
9/30/201679-170N/A-133N/A
6/30/201663-175N/A-145N/A
3/31/201650-169N/A-141N/A
12/31/201539-158N/A-134N/A
9/30/201527-150N/A-135N/A
6/30/201514-139N/A-119N/A
3/31/20156-120N/A-104N/A
12/31/20142-100N/A-81N/A
9/30/20141-80N/A-60N/A
6/30/20142-59N/A-46N/A
3/31/20143-52N/A-40N/A
12/31/20134-47N/A-40N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: EXAS is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.5%).

Earnings vs Market: EXAS is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: EXAS is expected to become profitable in the next 3 years.

Revenue vs Market: EXAS's revenue (11.1% per year) is forecast to grow faster than the US market (8.7% per year).

High Growth Revenue: EXAS's revenue (11.1% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: EXAS's Return on Equity is forecast to be low in 3 years time (5.8%).


Discover growth companies